Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.62 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.61 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL11587387 | 0.94 | HDAC1 (0.62) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL6737728 | 0.93 | HDAC6 (0.72) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL12604611 | 0.91 | EPHX2 (0.78) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL18868425 | 0.91 | EPHX2 (0.78) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL4981515 | 0.90 | EPHX2 (0.77) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL30918901 | 0.89 | EPHX2 (0.76) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL457082 | 0.87 | HDAC6 (0.79) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL28839185 | 0.86 | HDAC6 (0.70) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| SCHEMBL21454774 | 0.86 | HDAC6 (0.75) | HDAC6HDAC1EPHX2HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL3757721 | 0.85 | HDAC6 (0.76) | HDAC6HDAC1EPHX2HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029997-B2 | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2017175238-A1 | HIGHLY CHEMOSELECTIVE REACTIONS IN PRESENCE OF AROMATIC AMINO GROUPS | NEON LABORATORIES LIMITED (IN) | 2017-10-12 | — | — | WO | disclosed |
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2017-05-04 | — | — | US | disclosed |
| CN-105899496-A | OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS | 安达卢西亚健康服务部 | 2016-08-24 | — | — | CN | disclosed |
| CN-104478780-A | Acylpyrrole small-molecular organic compound, derivatives of organic compound as well as application and preparation method of acylpyrrole small-molecular organic compound and derivatives of organic compound | UNIV EAST CHINA NORMAL | 2015-04-01 | — | — | CN | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| CN-101952287-B | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2013-11-27 | — | — | CN | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| CN-101952287-A | Kinases inhibitor and application thereof | MERCK SERONO SA | 2011-01-19 | — | — | CN | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | GSK3B, HDAC1, HDAC3 | HDAC6 6/4885HDAC1 2/4885EPHX2 1891/4885 |
| US-10029997-B2 | Compositions and methods for treating cancers | HDAC3, HDAC1, GSK3B | HDAC6 5/4885HDAC1 2/4885EPHX2 1823/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | HDAC6 1564/4885HDAC1 1837/4885EPHX2 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.